← All trials
NCT06926387
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 17, 2025
- Primary completion
- Apr 19, 2025
- Completion date
- Apr 29, 2025
- First posted
- Apr 13, 2025
- Last posted
- May 13, 2025
- Enrollment
- 43
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yuhan Pharmaceutical CompanyLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.